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tases. The probability of regional lymph node
metastases is 3›5% in patients with a well to moderately
differentiated, superficially invasive primary tumour
confined to the uterine body.1 These women have to be
identified with a variety of preoperative and intra›
operative diagnostic procedures of limited accuracy.
In many centres, especially in Europe, gynaecolo›
gists do not perform lymphadenectomy when pelvic
lymph nodes are not suspicious. They argue that the
benefit of lymphadenectomy is unclear. Indeed, claims
of its intrinsic therapeutic value have been challenged.5
If lymphadenectomy is performed for diagnostic
reasons then histological findings in the nodes should
affect a decision on postoperative therapy, usually
radiotherapy. Yet many patients with tumour negative
nodes are referred for postoperative radiotherapy.3
Doubts about the effects of postoperative radio›
therapy in patients with adverse prognostic factors are
common.6 Dutch investigators have recently described
a randomised controlled trial of 714 women with
medium risk stage 1 endometrial carcinoma—well dif›
ferentiated tumours with deep (>50%) myometrial
invasion, moderately differentiated carcinoma with any
invasion, or poorly differentiated tumours with superfi›
cial ( < 50%) myometrial invasion.7 None of the
patients underwent lymphadenectomy. In the irradi›
ated group the five year locoregional recurrence rate
was 4% and the five year overall survival rate 81%. In
the non›irradiated (control) group these figures were
14% and 85% respectively. Mean follow up was 52
months. Thus these figures show no survival benefit
from postoperative radiotherapy. Ten (100/(14 − 4))
patients would have to be irradiated postoperatively
(46 Gy) to prevent one case of locoregional recurrence.
A total of 40 patients from the non›irradiated
group developed a locoregional relapse but only four
died from it. Because of the limited duration of obser›
vation the investigators propose waiting for more
mature results from salvage therapy before reaching
final conclusions. In general, locoregional recurrences
in non›irradiated patients are usually treated with
radiotherapy (70 Gy), with an estimated overall cure
rate of 67%.8
Based on the results from their trial the Dutch
investigators have proposed new guidelines for the use
of postoperative radiotherapy. They state that, in the
absence of survival benefit, postoperative radiotherapy
is justified when the absolute risk of locoregional
recurrence is > 10% or > 15% and the risk of uncon›
trolled local disease after salvage treatment is high. On
the basis of multivariate analysis they have identified
two subgroups. In women with either a moderately dif›
ferentiated, superficially invasive tumour or age < 60
years the risk of locoregional relapse is estimated to be
less than 5%. These women should not need
radiotherapy. In the remaining group (age >60 years
and superficially invasive, poorly differentiated tumour
or deeply invasive, well to moderately differentiated
tumour) the five year locoregional relapse rate is 18%
in the non›irradiated women and 5% in the irradiated
women. Here, 8 (100/(18 − 5)) patients need to be
treated to prevent one locoregional recurrence without
survival benefit.
According to the investigators, the grounds for
postoperative pelvic radiotherapy are to prevent
uncontrolled local disease and the physical and
psychological morbidity of the diagnosis and treat›
ment of a locoregional relapse. One has to ask whether
dying from uncontrolled disease outside the pelvis is
preferable to dying from disease in the pelvis. Given
the 14% locoregional relapse rate in the non›irradiated
group and 4% rate in the irradiated group, we estimate
that about 30% (4/14) of the locoregional relapses are
not prevented by radiation. Complications of radio›
therapy do occur in 25% of patients and are severe in
2%. What is the impact of these complications for psy›
chological functioning or more broader quality of life?
The great majority of the irradiated patients would
never have had a locoregional recurrence.
Adjuvant radiotherapy offers no survival benefit,
fails to prevent locoregional recurrence in about 30%
of patients, and harms many women who would never
develop such a recurrence. It seems justified to
abandon postoperative radiotherapy in patients with
medium risk stage1 endometrial carcinoma.
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Societal responsibilities of clinical trial sponsors
Lack of commercial pay off is not a legitimate reason for stopping a trial
Alarge long term randomised trial is a substantialcommitment by its sponsor, its principal scien›tific investigators, a complex international
organisational structure, and the patients who agree to
participate. For trials with commercial sponsorship, the
company’s business need—to demonstrate their treat›
ment’s advantage—should not conflict with society’s
need to enhance knowledge by conducting trials with
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unbiased designs and reporting results without statistical
distortion. For both trial sponsors and investigators a
tension exists between the “demonstrators” (I want to
prove that . . .) and the “scientists” (I want to find out if . . .).
The goal of regulatory guidelines,1 and indeed the best
intention of sponsors, is to ensure that the scientific
search for truth of public health relevance is what actu›
ally wins through. Another crucial ethical requirement is
that no patient should be knowingly harmed by partici›
pating in a trial: hence any trial should stop as soon as
the primary answer is clear. A paper in this week’s BMJ
(p 603)2 raises the issue of when else a trial might legiti›
mately be stopped.
Most major trials have an independent data moni›
toring committee that periodically and confidentially
inspects accumulating results for evidence of treatment
benefit or harm sufficient to merit stopping early.3 Sta›
tistical stopping guidelines exist for data monitoring
committees,4 5 and their collective wise judgment
requires very strong evidence of a new treatment’s
superiority in order to stop early. If a new treatment
appears harmful, such evidence “in the wrong
direction” usually needs not be so overwhelming to
stop the trial.6
A trial may also be stopped early on grounds of sci›
entific futility—that is, if the interim confidence interval
for the primary treatment difference is much more pes›
simistic than some minimum required true benefit. Even
though there is no clear evidence of inferiority, the trial
can validly be stopped because of an inadequate gain in
efficacy. Some prefer a conditional power argument
whereby if the interim data indicate that statistically sig›
nificant benefit is unlikely to be achieved on completion
of the trial then the trial may stop early. However, this
perhaps undesirably shifts the balance of intent back to
the “demonstrators” rather than the “scientists.” External
evidence, usually arising from other trials, may also
justify discontinuing a trial because the questions posed
by the trial have now been answered.
Less desirable circumstances are when a trial is
proceeding unsatisfactorily. For instance, inadequacies
in patient recruitment, compliance with treatment, or
quality of trial organisation can be serious enough to
affect a trial’s viability. Though errors of judgment and
bad planning are regrettable, the ethical stance should
be not to prolong research that “is going nowhere.”
This may also be important to non›commercial
sponsors with limited resources.
A different situation arises when the sponsor’s
error of commercial judgment rests in having started
the trial at all, as appears to be the case in the FAME
trial described this week by LiŁvre et al.2 Though such
a trial poses an important public health question—does
lipid lowering with fluvastatin reduce the risk of
cardiovascular events in elderly people?—the sponsor
thought that the commercial pay off of a positive result
became compromised by the fact that a similar trial of
another statin would finish earlier. From the sponsor’s
perspective this is also a “trial going nowhere” but the
difference is that it relates to commercial goals rather
than the scientific and public health intent, which were
still achievable.
Is such loss of interest by the sponsor another valid
circumstance in which to stop a trial early? In general,
we think not. It dangerously implies that business
needs can override both scientific intent and the ethical
obligation to patients already randomised. Are there
any mitigating circumstances or compromise posi›
tions? For instance, does one need two large trials of
essentially the same issue or could the class effect of
statins in the elderly be inferred from one definitive
trial? Could the FAME trial have been pared down by
completing follow up on patients already randomised
and combining this evidence with the other trial in a
meta›analysis? Could one argue that the scientific
question’s originality is compromised by the other
trial’s existence? We mention these issues in a spirit of
constructive debate, recognising that it is all too easy to
criticise commercial sponsors while clinical and scien›
tific collaborators also have their needs and disappoint›
ments that are not only about scientific altruism.
Nevertheless, it is commercial sponsors who most
seriously have to juggle the need for profit and the
research goal of societal benefit. It is great when the
two coincide but potentially ghastly when they conflict.
Though stopping a trial early for inappropriate
commercial reasons is clearly undesirable, it is not the
most serious fault relating to company sponsored
research. One could argue that it is worse to plan trials
in a way that could hide a treatment’s potential
inferiority. For instance, it has been argued that the
PROVE›IT trial comparing pravastatin with atorvasta›
tin in coronary heart disease has too short a follow up
to distinguish between true equivalence of patient ben›
efit and a treatment difference emerging after several
years.7 Also, trials may inadequately document a treat›
ment’s side effects because it is not in the sponsor’s
interest. Lastly, many opportunities exist to exaggerate
the true benefits of a treatment by statistical
manipulation or post hoc prioritisations in trial reports
or by overzealous marketing after regulatory approval.
Thus, the issue faced by companies, regulators, the
scientific community, and society is to recognise
potential conflict between the profit motive in a capital›
ist society and public health needs. The profit motive has
aided the development of many treatments of much
benefit to society. The general moral question is how we
ensure that the profit motive is kept in check so that it is
not at variance with patients’ best interests, whether by
enrolling them in trials going nowhere, as in FAME, or,
perhaps more importantly, drawing biased conclusions
on benefit and harm from less than ideal clinical trials.
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